Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060008 · ClinicalTrials.gov registry record · NA
Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
A NA study, sponsored by Children's Hospital of Philadelphia.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT00060008 is a NA study that was terminated before completion, run by Children's Hospital of Philadelphia. The registered enrollment target is 18 participants.
The verdict
NCT00060008, a NA study, was terminated before completion, sponsored by Children's Hospital of Philadelphia.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: New imaging procedures such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) and magnetic resonance (MR) perfusion imaging may improve the ability to detect disease progression, help doctors predict a patient's response to treatment, and help plan the most effective treatment. PURPOSE: This diagnostic trial is studying how well FDG-PET and MR perfusion imaging work in finding disease progression and determining response to treatment in patients with neurofibromatosis 1 and plexiform neurofibroma.
Interventions
- RADIATION fludeoxyglucose F 18
- RADIATION gadopentetate dimeglumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2002-04 |
| Est. Completion | 2011-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060008
The ClinicalTrials.gov registry entry for NCT00060008 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fludeoxyglucose F 18 is the first listed.
NCT00060008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060008 about?
NCT00060008 is a clinical study titled "Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma". RATIONALE: New imaging procedures such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) and magnetic resonance (MR) perfusion imaging may improve the ability to detect disease progression, help doctors predict a patient's response to treatment, and help plan the most effective treatmen...
What is the current status of trial NCT00060008?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2002-04. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00060008?
The interventions under investigation include: fludeoxyglucose F 18 (RADIATION), gadopentetate dimeglumine (RADIATION).
Who is sponsoring clinical trial NCT00060008?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.